Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)

NCT00744081 is registered in ClinicalTrials.gov with Goethe University as lead sponsor.

NCT NCT00744081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00744081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)
Lead sponsor
Goethe University
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2004
Completion date
December 31, 2010
Enrollment
130 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml